Outcomes of asymptomatic recombinant tissue plasminogen activator associated intracranial hemorrhage [PDF]
PLoS ONE, 2022 Background Intracranial hemorrhage (ICH) is the most devastating complication of recombinant tissue plasminogen activator (rtPA) treatment in acute ischemic stroke patients. Data on rtPA-associated asymptomatic ICH (aICH) are limited.
Chutithep Teekaput +4 more
doaj +3 more sources
Recombinant tissue plasminogen activator protects neurons after intracerebral hemorrhage through activating the PI3K/AKT/mTOR pathway [PDF]
Neural Regeneration ResearchRecombinant tissue plasminogen activator is commonly used for hematoma evacuation in minimally invasive surgery following intracerebral hemorrhage. However, during minimally invasive surgery, recombinant tissue plasminogen activator may come into contact
Jie Jing +9 more
doaj +2 more sources
Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series [PDF]
BMC Cardiovascular Disorders, 2020 Background Pericardial constriction is one of the complications of purulent pericarditis (PP). Most difficult to treat, which may develop both in early and in the late period of the disease, resulting in a very poor prognosis.
Małgorzata Dybowska +4 more
doaj +2 more sources
Acute Ischemic Stroke in Term Pregnancy Treated with Recombinant Tissue Plasminogen Activator [PDF]
Case Reports in Neurology, 2020 Recombinant tissue plasminogen activator (rtPA) may be considered in acute ischemic strokes (AIS) occurring in pregnancy. This recommendation is based on case reports which had demonstrated the efficiency and safety of rtPA in early pregnancy.
Sanjith Aaron +5 more
doaj +2 more sources
Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment [PDF]
Health Science Reports, 2021 Background and aims Thrombolytic therapy is widely used to treat acute ischemic stroke (AIS) patients. As intracerebral hemorrhage is a life‐threatening complication of this therapy, monitoring the fibrinolytic and coagulation systems is imperative ...
Yonge Liu +8 more
doaj +2 more sources
Incidence of Hemorrhagic Complications among Patients Treated with Thrombolytic in Erbil City, Iraq [PDF]
Al-Anbar Medical Journal, 2020 Background: Recombinant tissue-type plasminogen activator is an option of treatment for suspected occlusive vascular thrombi and its sequel (transmural myocardial infarction, pulmonary embolism, and ischemic stroke). The most important concern associated
Ahmed F. Hammad +2 more
doaj +1 more source
Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, 2023 Orolingual angioedema is a rare, but extremely dangerous complication of systemic thrombolytic therapy with recombinant tissue plasminogen activator, the incidence of which reaches 2.2-5.1 %.
E. A. Kovaleva +6 more
doaj +1 more source
Short-term Outcome in Ischemic Stroke Patients after Thrombolytic Therapy [PDF]
Zagazig University Medical Journal, 2022 Objective: Recombinant tissue plasminogen activator (rt-PA, alteplase), as the primary thrombolytic agent, has been proved effective and beneficial in patients with acute ischemic stroke (AIS).
Emad Agban +3 more
doaj +1 more source
Peripheral embolization following thrombolytic therapy for acute ischemic stroke—a case report
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020 Background Intravenous recombinant tissue plasminogen activator is the only golden approved medical therapy for acute ischemic stroke, guidelines for its injection relay on reducing or preventing associated hemorrhage as a side effect, yet hemorrhage is ...
Tamer Roushdy +5 more
doaj +1 more source
Women's Health, 2021 Introduction: There is an ongoing debate about the use of recombinant tissue plasminogen activator in acute stroke during pregnancy. The aim of our case report is to present that even in a small stroke centre intravenous thrombolysis can be used on a ...
Marek Bojda +4 more
doaj +1 more source